Lifeward Enters Strategic Partnership with Oramed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy LFWD?
Lifeward (LFWD) announced that it has entered into a transformative strategic partnership with Oramed Pharmaceuticals (ORMP). The transaction, which has received unanimous approval from Lifeward's board of directors and is subject to shareholder approval, includes Lifeward integrating Oramed's proprietary protein oral delivery technology and Oramed acquiring up to a 49.99% equity ownership in Lifeward. The investment structure provides Lifeward with access to up to approximately $47 million of capital through equity, convertible notes, milestone-based funding, and warrant coverage. This capital framework is designed to support Lifeward's path to profitability while enabling selective investment in high-value innovation. Under a clinical trial management agreement, Oramed will retain responsibility for managing and funding the anticipated POD clinical program. This structure allows Lifeward to maintain operational focus on profitability and cash generation, while retaining exposure to the potential upside of a large-scale biotech opportunity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFWD
Wall Street analysts forecast LFWD stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.640
Low
4.50
Averages
4.50
High
4.50
Current: 6.640
Low
4.50
Averages
4.50
High
4.50
About LFWD
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
Lifeward Regains Nasdaq Compliance
- Compliance Notification: Lifeward (LFWD) announced on Wednesday that Nasdaq has notified the company of its regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), marking a positive development in the company's stock price stability.
- Stock Performance: The company met the compliance requirement after its shares closed at $1 or more for 10 consecutive business days, achieving this milestone on March 9, 2026, which enhances investor confidence in the company's future prospects.
- Stock Price Increase: Lifeward's shares rose by 4.79%, reflecting the market's positive reaction to the company's compliance restoration, which may attract more investor interest and further bolster market confidence.
- Reverse Stock Split Plan: The company plans to implement a 1-for-12 reverse stock split, aimed at increasing the share price and enhancing shareholder value, while potentially paving the way for future capital operations.
See More
Lifeward Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Restoration: Lifeward Ltd. successfully maintained a closing bid price of $1.00 or more for 10 consecutive business days as of March 9, 2026, thereby satisfying Nasdaq Listing Rule 5550(a)(2), marking the resolution of prior compliance issues and ensuring its common stock continues to be listed on the Nasdaq Capital Market.
- Market Confidence Boost: This compliance restoration not only eliminates potential delisting risks for the company's stock but also enhances investor confidence in Lifeward, potentially facilitating future financing and market expansion opportunities, further driving innovation in the medical technology sector.
- Commitment to Product Innovation: Lifeward is dedicated to developing life-changing medical solutions, including the ReWalk exoskeleton and AlterG anti-gravity system, with a mission to improve the quality of life for individuals with physical disabilities, showcasing its leadership position in the industry.
- Global Business Strategy: Founded in 2001, Lifeward operates in the United States, Israel, and Germany, and its globalization strategy not only enhances its market competitiveness but also lays a foundation for future growth, particularly in the rapidly evolving medical technology market.
See More
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
- Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
- Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
- Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
Lifeward Regains Nasdaq Compliance
- Compliance Notification: Lifeward (LFWD) announced on Wednesday that Nasdaq has notified the company of its regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), marking a positive development in the company's stock price stability.
- Stock Performance: The company met the compliance requirement after its shares closed at $1 or more for 10 consecutive business days, achieving this milestone on March 9, 2026, which enhances investor confidence in the company's future prospects.
- Stock Price Increase: Lifeward's shares rose by 4.79%, reflecting the market's positive reaction to the company's compliance restoration, which may attract more investor interest and further bolster market confidence.
- Reverse Stock Split Plan: The company plans to implement a 1-for-12 reverse stock split, aimed at increasing the share price and enhancing shareholder value, while potentially paving the way for future capital operations.
See More
Lifeward Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Restoration: Lifeward Ltd. successfully maintained a closing bid price of $1.00 or more for 10 consecutive business days as of March 9, 2026, thereby satisfying Nasdaq Listing Rule 5550(a)(2), marking the resolution of prior compliance issues and ensuring its common stock continues to be listed on the Nasdaq Capital Market.
- Market Confidence Boost: This compliance restoration not only eliminates potential delisting risks for the company's stock but also enhances investor confidence in Lifeward, potentially facilitating future financing and market expansion opportunities, further driving innovation in the medical technology sector.
- Commitment to Product Innovation: Lifeward is dedicated to developing life-changing medical solutions, including the ReWalk exoskeleton and AlterG anti-gravity system, with a mission to improve the quality of life for individuals with physical disabilities, showcasing its leadership position in the industry.
- Global Business Strategy: Founded in 2001, Lifeward operates in the United States, Israel, and Germany, and its globalization strategy not only enhances its market competitiveness but also lays a foundation for future growth, particularly in the rapidly evolving medical technology market.
See More
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
- Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
- Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
- Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.
See More
